Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO

Philipp Harter*, Jalid Sehouli, Alexander Reuss, Annette Hasenburg, Giovanni Scambia, David Cibula, Sven Mahner, Ignace Vergote, Alexander Reinthaller, Alexander Burges, Lars Hanker, Martin Pölcher, Christian Kurzeder, Ulrich Canzler, Karl Ulrich Petry, Andreas Obermair, Edgar Petru, Barbara Schmalfeldt, Domenica Lorusso, Andreas Du Bois

*Korrespondierende/r Autor/-in für diese Arbeit
175 Zitate (Scopus)

Abstract

Purpose: The DESKTOP I trial proposed a score for the prediction of complete cytoreduction in recurrent ovarian cancer. Resectability was assumed if 3 factors were present: (1) complete resection at first surgery, (2) good performance status, and (3) absence of ascites. The DESKTOP II trialwas planned to verify this hypothesis prospectively in a multicenter setting. Methods: Participating centers prospectively enrolled all consecutive patients with platinumsensitive first or second relapse. The score was applied to all patients, but centers were free to decide on therapy. All further therapies were documented, and the outcome of patients was analyzed. A 75% complete resection rate in 110 prospectively classified patients had to be achieved to confirm a positive predictive value of 2 or higher of 3 with 95% probability. Results: Atotal of 516 patientswere screened within 19 months; of these, 261 patients (51%) were classified as score positive, and 129 patients with a positive score and first relapse were operated on. The rate of complete resection was 76%, thus confirming the validity of this score regarding positive prediction of complete resectability in 2 or more of 3 patients. Complication rates were moderate including second operations in 11% and perioperative mortality in 0.8%. Conclusions: This score is the first prospectively validated instrument to positively predict surgical outcome in recurrent ovarian cancer. It can aid in the selection of patients who might benefit from secondary cytoreductive surgery and will be enrolled in the recently started randomized prospective DESKTOP III trial investigating the role of surgery in recurrent platinum-sensitive ovarian cancer.

OriginalspracheEnglisch
ZeitschriftInternational Journal of Gynecological Cancer
Jahrgang21
Ausgabenummer2
Seiten (von - bis)289-295
Seitenumfang7
ISSN1048-891X
DOIs
PublikationsstatusVeröffentlicht - 02.2011

Fingerprint

Untersuchen Sie die Forschungsthemen von „Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren